Breast Cancer
Conditions
Keywords
HER2-enriched, Pyrotinib, neoadjuvant therapy, pCR
Brief summary
Breast cancer is kind of highly heterogeneous tumor. The patients with the same stage and with the same treatment regimen, their prognosis varies greatly, mainly due to the different phenotypes of breast cancer and different sensitivities to drug therapy. PMA50 and BluePrint classification divides breast cancer into other inherent subtypes: Luminal A, Luminal B, HER2-enriched (HER2-E) and Basal-like. Previous studies have shown that these patients with inherent subtype of HER2-enriched are more likely to obtain higher pCR after anti-HER2 therapy. And more study and meta analysis had demonstrated the higher pCR is closely related to EFS. The genetic and molecular typing of breast cancer is closely related to the prognosis of breast cancer, so it is imperative to seek a new treatment regimen for precision treatment and maximize the therapeutic benefit of HER2-enriched patients.
Interventions
DRUGPyrotinib, trastuzumab, paclitaxel-albumin
pyrotinib: 400mg orally daily; trastuzumab: 8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 6 cycles; paclitaxel-albumin: 260mg/m2, every 3 week, a total of 6 cycles
Sponsors
Jiangsu HengRui Medicine Co., Ltd.
The First Affiliated Hospital with Nanjing Medical University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. female patients, 18 years ≤ age ≤ 75 years； 2. Performance Status- Eastern Cooperative Oncology Group (ECOG) 0-1 3. Histologically confirmed invasive breast cancer（early stage or locally advanced） 4. HER2 positive (HER2+++ by IHC or FISH+), and the HER2-enriched subtype screened by BulePrint test; 5. Primary breast cancer; 6. Known hormone receptor status. 7. The organs are functioning normally, like the liver function, the renal function， and the baseline left ventricular ejection fraction (LVEF)≥55% measured by ECHO 8. Signed informed consent form (ICF)
Exclusion criteria
1. metastatic disease (Stage IV) or inflammatory breast cancer 2. Previous or current history of malignant neoplasms, except for curatively treated:Basal and squamous cell carcinoma of the skin,Carcinoma in situ of the cervix. 3. Clinically relevant cardiovascular disease:Known history of uncontrolled or symptomatic angina, clinically significant arrhythmias, congestive heart failure, transmural myocardial infarction, uncontrolled hypertension ≥180/110); 4. A history of allergy to the drugs in this study； 5. Unable or unwilling to swallow tablets
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With Pathological Complete Response (pCR) at the Time of Surgery evaluated by the investigators | Approximately 5 months from randomization following surgery or early withdrawal, whichever occurred first (Surgery was performed within 4 weeks after Cycle 6, each cycle is 21 days) | pCR |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Event-free survival | Following surgery until year 2 | EFS |
| Objective Response Rate | Baseline up to cycle 6 (assessed at Baseline, at the time of pre-surgery), up to approximately 5 months after neoadjuvant (each cycle is 21 days) | ORR |
| minimal residual lesions | Following surgery until year 2 | MRD |
Countries
China
Contacts
Primary ContactWenbin Zhou, Professor
Outcome results
None listed